Key facts
- BiomEdit’s last known valuation is $577.0M (Feb 2023).
- It has raised $55.1M across 2 recorded rounds; the latest was Early Stage VC ($16.0M) in Apr 2025.
- Notable investors include Viking Global Investors, Gates Foundation, Elevate Ventures, Ginkgo Bioworks, AgriZeroNZ — 10 tracked in total.
- BiomEdit has filed 1 Form D with the SEC, most recently Jun 2025 ($16.0M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for BiomEdit
Funding rounds
2 roundsAbout BiomEdit
Developer of a microbiome innovation platform designed to discover and develop animal health products. The company's platform utilizes microbiome-derived bioactive compounds and engineered microbial medicines to address unmet needs in animal health, enabling clients to enhance animal protein production and improve livestock disease monitoring.
- Industry
- Other Agriculture
- Sector
- Materials and Resources
- HQ
- Greenfield, IN, United States
- Founded
- 2022
- Employees
- 35
- Website
- biomedit.com/
- Ownership
- Privately Held (backing)
BiomEdit doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BiomEdit shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BiomEdit in its N-PORT filings yet. We sweep new filings monthly.